Background
Group of phase III first-line RCTs of erlotinib vs platinum chemotherapy in EGFR-mutated (ex19del/L858R) advanced NSCLC. EURTAC: N=174, European. OPTIMAL: N=154, stage IIIB/IV, Chinese. ENSURE: N=270 (Asian), stage IIIB/IV.
Interventions and follow up
Arm A: Erlotinib 150 mg PO daily until progression
Arm B: Platinum doublet chemotherapy (EURTAC: cisplatin + docetaxel/gemcitabine x4; OPTIMAL: gemcitabine + carboplatin x4; ENSURE: gemcitabine + cisplatin)
Primary endpoint: PFS
Arm B: Platinum doublet chemotherapy (EURTAC: cisplatin + docetaxel/gemcitabine x4; OPTIMAL: gemcitabine + carboplatin x4; ENSURE: gemcitabine + cisplatin)
Primary endpoint: PFS
Results
EURTAC mPFS: 9.7 mo vs 5.2 mo; HR 0.37 (95%CI 0.25–0.54)
EURTAC mOS: 19.3 mo vs 19.5 mo; HR 1.04 (95%CI 0.65–1.68)
OPTIMAL mPFS: 13.1 mo vs 4.6 mo; HR 0.16 (95%CI 0.10–0.26)
OPTIMAL mOS: 22.8 mo vs 27.2 mo; HR 1.19 (95%CI 0.83–1.71)
ENSURE mPFS: 11.0 mo vs 5.5 mo; HR 0.34 (95%CI 0.22–0.51)
ENSURE mOS: 26.3 mo vs 25.5 mo; HR 0.91 (95%CI 0.63–1.31)
EURTAC mOS: 19.3 mo vs 19.5 mo; HR 1.04 (95%CI 0.65–1.68)
OPTIMAL mPFS: 13.1 mo vs 4.6 mo; HR 0.16 (95%CI 0.10–0.26)
OPTIMAL mOS: 22.8 mo vs 27.2 mo; HR 1.19 (95%CI 0.83–1.71)
ENSURE mPFS: 11.0 mo vs 5.5 mo; HR 0.34 (95%CI 0.22–0.51)
ENSURE mOS: 26.3 mo vs 25.5 mo; HR 0.91 (95%CI 0.63–1.31)
Adverse events
Skin/nail: acneiform rash, nail changes, skin cracks, radiation-recall reactions, increased hair fragility/hirsutism, eyelash/eyebrow thickening, hair loss
GI: diarrhea; GI bleed
Lab changes: elevated LFTs
Pulmonary: cough, dyspnea (ILD)
Ocular: keratoconjunctivitis
PK notes: oral bioavailability 60% fasting, ~100% with food; avoid PPI/H2 (high pH lowers level) or separate by 12 h (PPI)/6 h (H2); less active in active smokers
GI: diarrhea; GI bleed
Lab changes: elevated LFTs
Pulmonary: cough, dyspnea (ILD)
Ocular: keratoconjunctivitis
PK notes: oral bioavailability 60% fasting, ~100% with food; avoid PPI/H2 (high pH lowers level) or separate by 12 h (PPI)/6 h (H2); less active in active smokers
Conclusions
Erlotinib improved PFS but not OS (likely from crossover) vs chemotherapy in first-line EGFR-mutated advanced NSCLC; historical evidence establishing TKI over chemotherapy.
Key Limitations
OS confounded by crossover; mostly Asian populations (OPTIMAL/ENSURE) limit generalizability; superseded by osimertinib (FLAURA) which has superior CNS activity and OS; no head-to-head among these TKIs.
Clinical Context
Erlotinib FDA approved for EGFR ex19del/L858R first-line (2013). ESMO/ASCO now favor osimertinib first-line; first-generation TKIs are alternatives where osimertinib is unavailable. Erlotinib+bevacizumab/ramucirumab improve PFS only.